Tag: cancer biologics market analysis

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Cancer biologics Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?

The cancer biologics market has experienced substantial growth in recent years. This market is projected to expand from $129.05 billion in 2025 to $140.88 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. Historically, this expansion can be linked to several factors, including the escalating global prevalence of cancer, the increasing need for advanced cancer treatments, intensified oncology research endeavors, the perceived inadequacy of traditional chemotherapy, and the proliferation of hospital-based cancer treatment facilities.

The cancer biologics market is anticipated to show considerable growth in the upcoming years. It is projected to expand to $203.29 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. The expansion during this forecast period can be attributed to breakthroughs in cell and gene therapy platforms, a growing number of novel biologic approvals, the rise of personalized oncology treatments, increased investment in cancer biologics research and development, and an expansion of manufacturing capacity for biologics. Key trends during this period include a heightened adoption of immunotherapy and targeted biologic treatments, increased utilization of monoclonal antibodies in oncology, the proliferation of cell and gene therapy-based cancer solutions, an expansion of cancer vaccine development programs, and an intensified focus on combination biologic therapies.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cancer biologics Market Growth Momentum: What Factors Are Shaping Demand?

A significant driver for the expansion of the cancer biologics market is the increasing occurrence of chronic diseases. These long-term conditions impair the well-being of individuals, including those with disabilities, and cancer stands out as one of the prevalent chronic illnesses. Common forms of cancer include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, reports from February 2024 by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated that an increasing number of people in America are dealing with multiple chronic conditions, with 42% affected by two or more, and 12% by five or more. Consequently, the rising prevalence of chronic diseases is projected to stimulate the growth of the cancer biologics market in the upcoming years.

Cancer biologics Market Segment Outlook: Which Categories Are Growing Fastest?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

Cancer biologics Market Trends Redefining Industry Growth

Leading firms within the cancer biologics market are concentrating on creating novel therapies, including bispecific antibodies and biomarker guided biologics, with the goal of improving treatment effectiveness and more precisely targeting particular cancer cells. Bispecific antibodies represent an advanced biologic treatment capable of simultaneously attaching to two different epitopes or targets, whereas biomarker guided biologics are formulated to selectively target tumor cells characterized by specific molecular markers. An example of this is seen in November 2024, when Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical firm based in Dublin, secured U.S. Food & Drug Administration (FDA) approval for the accelerated status of Ziihera (zanidatamab hrii). This was for the treatment of adults diagnosed with previously treated, unresectable, or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC). This approval signifies the introduction of the first and only dual HER2 targeted bispecific antibody for this particular indication, thereby broadening the scope of HER2 targeted biologic therapy to encompass a new tumor type, moving beyond traditional applications.

Cancer biologics Market Leading Companies And Competitive Benchmarking

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

View The Full Cancer biologics Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Cancer biologics Market Regional Analysis And Leading Geography

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Cancer biologics Market Expected To Reach $203.28 Billion By 2030 At 9.6% CAGR

The market for cancer biologics has experienced robust expansion in recent times. Its value is projected to increase from $129.05 billion in 2025 to $140.88 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.2%. This historical growth has been driven by factors such as the global rise in cancer incidence, heightened demand for sophisticated cancer treatments, intensified efforts in oncology research, the constrained efficacy of traditional chemotherapy, and the proliferation of hospital-based cancer care facilities.

The cancer biologics market is projected to experience robust expansion over the coming years, reaching $203.29 billion by 2030 with a compound annual growth rate (CAGR) of 9.6%. This projected growth during the forecast period is driven by progress in cell and gene therapy platforms, the growing number of approvals for new biologic drugs, the rise of personalized oncology approaches, increased funding for cancer biologics research and development, and the scaling up of biologics production capabilities. Key developments expected to shape this period include the increasing use of immunotherapy and targeted biologic therapies, the broader application of monoclonal antibodies in cancer treatment, the emergence of cell and gene therapy-based oncological interventions, the advancement of cancer vaccine initiatives, and a heightened emphasis on precision biologic strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cancer biologics Market Demand Drivers Creating New Revenue Opportunities

The increasing occurrence of chronic illnesses is a key factor fueling expansion in the cancer biologics market. These conditions, which last for extended periods and impair the well-being of those affected, include cancer as one of the most prevalent. Common types of cancer are breast, lung and bronchus, prostate, colon and rectum, skin melanoma, bladder, non-Hodgkin lymphoma, kidney and renal pelvis, endometrial, leukemia, pancreatic, thyroid, and liver cancers. As an example, data released in February 2024 by the Centers for Disease Control and Prevention (CDC)—a public health organization based in the United States—indicated that a rising number of Americans are dealing with multiple chronic conditions: 42% have two or more, while 12% face five or more. Because of this, the growing prevalence of chronic diseases is anticipated to drive the cancer biologics market in the years ahead.

Cancer biologics Market Segmentation And Category Breakdown

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

Cancer biologics Market Trends Driving Strategic Industry Expansion

Major players in the cancer biologics space are prioritizing the creation of cutting-edge treatments, including bispecific antibodies and biomarker-driven biologics, to boost therapeutic effectiveness and better zero in on particular cancer cells. Bispecific antibodies represent a next-generation biologic approach capable of engaging two separate epitopes or targets at once, whereas biomarker-guided biologics are engineered to precisely attack tumor cells identified through specific molecular indicators. As an example, in November 2024, as reported by Jazz Pharmaceuticals Public Limited Company, a Dublin-headquartered global biopharmaceutical firm, the U.S. Food & Drug Administration (FDA) granted accelerated approval for Ziihera (zanidatamab hrii) to treat adults with previously treated, unresectable or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC). This authorization marks the first and only dual HER2-targeted bispecific antibody to receive approval for this particular indication, thus extending the application of HER2-focused biologic therapy to a new cancer type beyond its previous scope.

Cancer biologics Market Competitive Analysis Of Major Industry Participants

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

Access The Complete Cancer biologics Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cancer biologics Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The Cancer biologics Market In 2026 And How Much Will It Reach By 2030?

The cancer biologics market size has seen robust growth in recent years. It is projected to expand from $129.05 billion in 2025 to $140.88 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.2%. This historical expansion is attributable to factors such as the increasing global prevalence of cancer, a growing demand for advanced cancer therapies, heightened oncology research activities, the limited effectiveness of conventional chemotherapy, and the proliferation of hospital-based cancer treatment centers.

The cancer biologics market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach **$203.29 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%.** This projected growth is driven by several factors, including breakthroughs in cell and gene therapy platforms, an increase in approvals for new biologics, the expansion of personalized oncology treatments, greater investment in research and development for cancer biologics, and increased biologics manufacturing capabilities. Key developments expected during this period involve the increasing embrace of immunotherapy and targeted biologic treatments, a greater application of monoclonal antibodies in oncology, the proliferation of cell and gene therapy-based cancer interventions, the broadening of cancer vaccine development initiatives, and an intensified focus on combination biologic therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

What Important Drivers Are Powering The Cancer biologics Market Growth?

The increasing prevalence of chronic diseases stands as a significant factor driving the growth of the cancer biologics market. Chronic disorders are conditions that endure over prolonged periods, impairing the health of affected individuals, with cancer being a prevalent example of such a chronic disease. The most commonly observed cancers include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, in February 2024, data published by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated that an expanding proportion of people in America are contending with multiple chronic conditions, with 42% having two or more, and 12% dealing with five or more. Consequently, the rising occurrence of chronic diseases is expected to propel the cancer biologics market’s expansion in the years ahead.

What Key Segment Areas Are Included In The Cancer biologics Market Assessment?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

Which Trends Are Influencing The Direction Of The Cancer biologics Market?

Major companies in the cancer biologics market are prioritizing the development of innovative therapies like bispecific antibodies and biomarker guided biologics to boost treatment efficacy and more effectively pinpoint specific cancer cells. Bispecific antibodies are a next-generation biologic approach that can simultaneously bind to two distinct epitopes or targets, while biomarker guided biologics are tailored to specifically target tumor cells identified through certain molecular markers. For instance, in November 2024, Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical company based in Dublin, secured approval from the U.S. Food & Drug Administration (FDA) for the accelerated approval of Ziihera (zanidatamab hrii) for adults suffering from previously treated, unresectable or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC). This approval signifies the introduction of the first and only dual HER2 targeted bispecific antibody for this specific indication, thereby extending the reach of HER2 targeted biologic therapy into a new type of tumor beyond its conventional applications.

Which Firms Are Competing In The Cancer biologics Market?

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

Access The Complete Cancer biologics Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

What Is The Largest Regional Market In The Cancer biologics Market?

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cancer biologics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

Browse Through More Reports Similar to the Global Cancer biologics Market 2026, By The Business Research Company

Point Of Care Diagnostics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Cell Culture Consumables And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Metabolomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Cancer biologics Market Expected To Scale Between 2026 And 2030?

The cancer biologics market has demonstrated significant growth in recent years. It is projected to increase from $129.05 billion in 2025 to $140.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical expansion can be attributed to factors like the rising global prevalence of cancer, increasing demand for advanced cancer therapies, heightened oncology research activities, the limited efficacy of conventional chemotherapy, and the expansion of hospital-based cancer treatment centers.

The cancer biologics market size is expected to undergo significant growth over the next few years, projected to reach $203.29 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This expansion during the forecast period is primarily attributed to advancements in cell and gene therapy platforms, an increase in approvals for novel biologics, the growth of personalized oncology treatments, rising investment in cancer biologics research and development, and the expansion of biologics manufacturing capacity. Major trends expected in this period include the increasing adoption of immunotherapy and targeted biologic treatments, a greater utilization of monoclonal antibodies in oncology, the growth of cell and gene therapy-based cancer treatments, the expansion of cancer vaccine development programs, and a heightened focus on combination biologic therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

What Key Factors Are Shaping The Cancer biologics Market Landscape?

The increasing occurrence of chronic diseases is a primary catalyst fueling the expansion of the cancer biologics market. These long-lasting health conditions, which impair individuals’ well-being, include cancer as one of the most widespread. The most frequently observed cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, in February 2024, data released by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, revealed that a growing number of Americans are managing several chronic conditions, with 42% experiencing two or more, and 12% contending with five or more. Therefore, the escalating prevalence of chronic diseases is anticipated to drive the cancer biologics market’s growth in the coming years.

Which Segment Classifications Are Used In The Cancer biologics Market Segment Analysis?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

What Emerging Trends Are Seen In The Cancer biologics Market?

Leading companies in the cancer biologics market are dedicated to developing novel treatments like bispecific antibodies and biomarker guided biologics, aiming to boost treatment effectiveness and more precisely target specific cancer cells. Bispecific antibodies represent an advanced biologic therapy designed to simultaneously attach to two distinct epitopes or targets, while biomarker guided biologics are crafted to specifically attack tumor cells identified by particular molecular markers. For example, in November 2024, the U.S. Food & Drug Administration (FDA) granted accelerated approval to Ziihera (zanidatamab hrii) for adults suffering from previously treated, unresectable, or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC), as reported by the Dublin-based global biopharmaceutical company, Jazz Pharmaceuticals Public Limited Company. This approval establishes Ziihera as the first and only dual HER2 targeted bispecific antibody for this indication, thereby extending the utility of HER2 targeted biologic therapy into a new tumor type beyond conventional uses.

Which Firms Are Contributing To The Cancer biologics Market Ecosystem?

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

Get The Full Cancer biologics Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Which Region Has The Greatest Market Share In The Cancer biologics Market?

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer biologics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Browse Through More Reports Similar to the Global Cancer biologics Market 2026, By The Business Research Company

Point Of Care Diagnostics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Cell Culture Consumables And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Metabolomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Cancer biologics Market Over The Period 2026–2030?

The cancer biologics market size has demonstrated significant growth in recent years. It is anticipated to increase from $129.05 billion in 2025 to $140.88 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.2%. This expansion during the historical period is primarily due to several factors: a rising global prevalence of cancer, an increasing demand for sophisticated cancer therapies, intensified oncology research initiatives, the inherent limitations of conventional chemotherapy, and the broadening network of hospital-based cancer treatment centers.

The cancer biologics market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $203.29 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This projected growth during the forecast period is primarily driven by progress in cell and gene therapy platforms, a rise in approvals for new biologics, the expansion of personalized oncology therapies, increased investment in research and development for cancer biologics, and an increase in biologics manufacturing capabilities. Key trends expected during this period involve the greater adoption of immunotherapy and targeted biologic treatments, a growing application of monoclonal antibodies in oncology, the development of cell and gene therapy-based approaches for cancer, an increase in cancer vaccine development initiatives, and an enhanced emphasis on combination biologic therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

What Drivers Are Expected To Influence The Cancer biologics Market During The Forecast Period?

The increasing incidence of chronic diseases stands as a primary catalyst for the expansion of the cancer biologics market. Chronic disorders, defined as long-lasting conditions that negatively impact the health of individuals, count cancer among their most prevalent forms. Commonly identified cancers encompass breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, reports published in February 2024 by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicate that a growing number of people in America manage multiple chronic conditions, with 42% having two or more and 12% experiencing five or more. Thus, the rising prevalence of chronic diseases is expected to stimulate the cancer biologics market growth in the coming years.

How Is The Cancer biologics Market Divided Into Its Major Segments?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

How Are Trends Transforming The Cancer biologics Market Landscape?

Leading companies in the cancer biologics market are prioritizing the development of innovative treatments, such as bispecific antibodies and biomarker-guided biologics, to enhance treatment efficacy and more effectively target specific cancer cells. Bispecific antibodies are an advanced biologic therapy designed to bind to two separate epitopes or targets concurrently, while biomarker-guided biologics are specifically engineered to target tumor cells identified by particular molecular markers. For instance, in November 2024, Jazz Pharmaceuticals Public Limited Company, a Dublin-based global biopharmaceutical company, received acceleration approval from the U.S. Food & Drug Administration (FDA) for Ziihera (zanidatamab hrii) for adults with previously treated, unresectable or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC). This approval signifies the first and only dual HER2 targeted bispecific antibody for this indication, thereby extending the application of HER2-targeted biologic therapy into a new tumor type beyond its classical indications.

Who Are The Prominent Organizations Shaping The Cancer biologics Market?

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

Read the full cancer biologics market report here:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Which Region Is Forecast To Lead The Cancer biologics Market In Terms Of Market Size?

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer biologics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2563&type=smp

Browse Through More Reports Similar to the Global Cancer biologics Market 2026, By The Business Research Company

Point Of Care Diagnostics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Cell Culture Consumables And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Metabolomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Cancer biologics Market Over The Period 2026–2030?

The cancer biologics market size has demonstrated significant growth in recent years. It is anticipated to increase from $129.05 billion in 2025 to $140.88 billion in 2026, driven by a compound annual growth rate (CAGR) of 9.2%. This expansion during the historical period is primarily due to several factors: a rising global prevalence of cancer, an increasing demand for sophisticated cancer therapies, intensified oncology research initiatives, the inherent limitations of conventional chemotherapy, and the broadening network of hospital-based cancer treatment centers.

The cancer biologics market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $203.29 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This projected growth during the forecast period is primarily driven by progress in cell and gene therapy platforms, a rise in approvals for new biologics, the expansion of personalized oncology therapies, increased investment in research and development for cancer biologics, and an increase in biologics manufacturing capabilities. Key trends expected during this period involve the greater adoption of immunotherapy and targeted biologic treatments, a growing application of monoclonal antibodies in oncology, the development of cell and gene therapy-based approaches for cancer, an increase in cancer vaccine development initiatives, and an enhanced emphasis on combination biologic therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

What Drivers Are Expected To Influence The Cancer biologics Market During The Forecast Period?

The increasing incidence of chronic diseases stands as a primary catalyst for the expansion of the cancer biologics market. Chronic disorders, defined as long-lasting conditions that negatively impact the health of individuals, count cancer among their most prevalent forms. Commonly identified cancers encompass breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, reports published in February 2024 by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicate that a growing number of people in America manage multiple chronic conditions, with 42% having two or more and 12% experiencing five or more. Thus, the rising prevalence of chronic diseases is expected to stimulate the cancer biologics market growth in the coming years.

How Is The Cancer biologics Market Divided Into Its Major Segments?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

How Are Trends Transforming The Cancer biologics Market Landscape?

Leading companies in the cancer biologics market are prioritizing the development of innovative treatments, such as bispecific antibodies and biomarker-guided biologics, to enhance treatment efficacy and more effectively target specific cancer cells. Bispecific antibodies are an advanced biologic therapy designed to bind to two separate epitopes or targets concurrently, while biomarker-guided biologics are specifically engineered to target tumor cells identified by particular molecular markers. For instance, in November 2024, Jazz Pharmaceuticals Public Limited Company, a Dublin-based global biopharmaceutical company, received acceleration approval from the U.S. Food & Drug Administration (FDA) for Ziihera (zanidatamab hrii) for adults with previously treated, unresectable or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC). This approval signifies the first and only dual HER2 targeted bispecific antibody for this indication, thereby extending the application of HER2-targeted biologic therapy into a new tumor type beyond its classical indications.

Who Are The Prominent Organizations Shaping The Cancer biologics Market?

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

Read the full cancer biologics market report here:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Which Region Is Forecast To Lead The Cancer biologics Market In Terms Of Market Size?

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer biologics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2563&type=smp

Browse Through More Reports Similar to the Global Cancer biologics Market 2026, By The Business Research Company

Point Of Care Diagnostics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Cell Culture Consumables And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Metabolomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer biologics market from 2026–2035 with trusted insights from The Business Research Company

How much is the Cancer biologics Market valued at in 2026, and what valuation is forecast for 2030?

The cancer biologics market has experienced strong growth in recent years. It is projected to expand from $129.05 billion in 2025 to $140.88 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.2%. The historical growth of this market can be attributed to an increasing global incidence of cancer, a rising need for advanced cancer therapies, intensified oncology research endeavors, the recognized limitations of conventional chemotherapy, and the proliferation of hospital-based cancer treatment centers.

The cancer biologics market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $203.29 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. Key factors driving this growth during the forecast timeframe include progress in cell and gene therapy platforms, a rise in approvals for new biologics, the expansion of personalized oncology therapies, increased investment in cancer biologics research and development (R&D), and an increase in biologics manufacturing capabilities. Prominent trends expected during this period involve a growing embrace of immunotherapy and targeted biologic interventions, the expanded application of monoclonal antibodies within oncology, the development of cell and gene therapy solutions for cancer, an increase in cancer vaccine development initiatives, and an enhanced emphasis on combination biologic treatments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2563&type=smp

What Drivers Are Influencing The Growth Of The Cancer biologics Market?

The increasing incidence of chronic diseases is a primary driver behind the expansion of the cancer biologics market. These long-term conditions impair the health of individuals, including those with disabilities, with cancer being one of the most prevalent chronic illnesses. The most frequently encountered cancers include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For instance, in February 2024, reports from the Centers for Disease Control and Prevention (CDC), a US-based public health agency, revealed that a growing number of people in America are dealing with multiple chronic conditions, with 42% experiencing two or more, and 12% having five or more. Thus, the rising prevalence of chronic diseases is projected to propel the growth of the cancer biologics market in the coming years.

What Segments Are Included Within The Cancer biologics Market?

The cancer biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types

2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications

3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines

3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy

4) By Other Types: Cytokines, Growth Factors, Fusion Proteins

Which Market Trends Are Opening Growth Opportunities In The Cancer biologics Market?

Major companies active within the cancer biologics market are primarily focusing on the development of innovative therapies, such as bispecific antibodies and biomarker guided biologics. This strategic emphasis aims to enhance treatment efficacy and target particular cancer cells more effectively. Bispecific antibodies are considered a next-generation biologic therapy, capable of binding concurrently to two distinct epitopes or targets, while biomarker guided biologics are specifically designed to target tumor cells identified through certain molecular markers. For example, in November 2024, the Dublin-based global biopharmaceutical company, Jazz Pharmaceuticals Public Limited Company, received approval from the U.S. Food & Drug Administration (FDA) for the accelerated pathway of Ziihera (zanidatamab hrii). This was granted for adults with previously treated, unresectable or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC). This approval signifies the first and only dual HER2 targeted bispecific antibody for this specific indication, thereby extending the application of HER2 targeted biologic therapy into a new tumor type, moving beyond established indications.

Who Are The Core Companies Influencing Trends In The Cancer biologics Market?

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Which Regions Are Projected To Dominate The Cancer biologics Market In The Coming Years?

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cancer biologics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2563&type=smp

Browse Through More Reports Similar to the Global Cancer biologics Market 2026, By The Business Research Company

Point Of Care Diagnostics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

Cell Culture Consumables And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Metabolomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model